Literature DB >> 26368360

Does deficiency of von Willebrand factor protect against cardiovascular disease? Analysis of a national discharge register.

C D Seaman1,2, J Yabes3, D M Comer3, M V Ragni1,2.   

Abstract

INTRODUCTION: von Willebrand factor (VWF) plays a critical role in platelet adhesion and aggregation after vascular injury and at sites of high shear rate. Elevated VWF levels are associated with an increased risk of ischemic cardiovascular events; however, it is unclear whether VWF deficiency is protective against atherosclerosis. We aimed to compare the prevalence of cardiovascular disease (CVD) among patients with and without von Willebrand disease (VWD).
METHODS: A cross-sectional analysis was performed on discharge data for adults from the Nationwide Inpatient Sample (NIS) between the years 2009 and 2011. CVD was defined as ischemic heart disease, myocardial infarction, ischemic cerebrovascular disease, or peripheral vascular disease. For prevalence calculations and statistical analyses, we used discharge-level weights provided by the NIS to reflect national estimates. CVD was compared across groups by use of the Rao-Scott chi-square test. Multivariable logistic regression was used to estimate the likelihood of CVD in VWD patients after adjustment for age, gender, and CVD-related risk factors.
RESULTS: The prevalence of CVD in VWD patients was less than the prevalence of CVD in non-VWD patients (15.0% versus 26.0%). VWD was associated with a decreased likelihood of CVD after adjustment for age, gender, and CVD-related risk factors (odds ratio 0.85; 95% confidence interval 0.79-0.92). DISCUSSION: These findings indicate that the risk of CVD is decreased among VWD patients, and that VWF deficiency may be protective against CVD.
© 2015 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  cardiovascular disease; thrombosis; von Willebrand disease; von Willebrand factor; von Willebrand factor deficiency

Mesh:

Substances:

Year:  2015        PMID: 26368360     DOI: 10.1111/jth.13142

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  15 in total

Review 1.  How I treat patients with inherited bleeding disorders who need anticoagulant therapy.

Authors:  Karlyn Martin; Nigel S Key
Journal:  Blood       Date:  2016-04-22       Impact factor: 22.113

2.  Perioperative bleeding and thrombotic risks in patients with Von Willebrand disease.

Authors:  Nathaniel R Smilowitz; Navdeep Gupta; Yu Guo; Sripal Bangalore; Jeffrey S Berger
Journal:  J Thromb Thrombolysis       Date:  2017-07       Impact factor: 2.300

3.  Blood volume-based von Willebrand factor to prevent postpartum hemorrhage in von Willebrand disease.

Authors:  Margaret V Ragni
Journal:  Blood Adv       Date:  2017-04-25

4.  The Cardioprotective Potential of von Willebrand Disease in Ischemic Heart Disease.

Authors:  Nawfal Mihyawi; Muhammad Ajmal; Ayman R Fath; Bikash Bhattarai; Beeletsega Yeneneh
Journal:  Tex Heart Inst J       Date:  2022-07-01

Review 5.  Regulation of VWF expression, and secretion in health and disease.

Authors:  Yaozu Xiang; John Hwa
Journal:  Curr Opin Hematol       Date:  2016-05       Impact factor: 3.284

6.  Association of von Willebrand factor deficiency with prevalent cardiovascular disease and asymptomatic carotid atherosclerosis: The Atherosclerosis Risk in Communities Study.

Authors:  Craig D Seaman; Kristen M George; Margaret Ragni; Aaron R Folsom
Journal:  Thromb Res       Date:  2016-06-02       Impact factor: 3.944

7.  Clot Permeability, Agonist Transport, and Platelet Binding Kinetics in Arterial Thrombosis.

Authors:  Jian Du; Dongjune Kim; Ghadah Alhawael; David N Ku; Aaron L Fogelson
Journal:  Biophys J       Date:  2020-10-14       Impact factor: 4.033

8.  Genome-Wide Association Transethnic Meta-Analyses Identifies Novel Associations Regulating Coagulation Factor VIII and von Willebrand Factor Plasma Levels.

Authors:  Maria Sabater-Lleal; Jennifer E Huffman; Paul S de Vries; Jonathan Marten; Michael A Mastrangelo; Ci Song; Nathan Pankratz; Cavin K Ward-Caviness; Lisa R Yanek; Stella Trompet; Graciela E Delgado; Xiuqing Guo; Traci M Bartz; Angel Martinez-Perez; Marine Germain; Hugoline G de Haan; Ayse B Ozel; Ozren Polasek; Albert V Smith; John D Eicher; Alex P Reiner; Weihong Tang; Neil M Davies; David J Stott; Jerome I Rotter; Geoffrey H Tofler; Eric Boerwinkle; Moniek P M de Maat; Marcus E Kleber; Paul Welsh; Jennifer A Brody; Ming-Huei Chen; Dhananjay Vaidya; José Manuel Soria; Pierre Suchon; Astrid van Hylckama Vlieg; Karl C Desch; Ivana Kolcic; Peter K Joshi; Lenore J Launer; Tamara B Harris; Harry Campbell; Igor Rudan; Diane M Becker; Jun Z Li; Fernando Rivadeneira; André G Uitterlinden; Albert Hofman; Oscar H Franco; Mary Cushman; Bruce M Psaty; Pierre-Emmanuel Morange; Barbara McKnight; Michael R Chong; Israel Fernandez-Cadenas; Jonathan Rosand; Arne Lindgren; Vilmundur Gudnason; James F Wilson; Caroline Hayward; David Ginsburg; Myriam Fornage; Frits R Rosendaal; Juan Carlos Souto; Lewis C Becker; Nancy S Jenny; Winfried März; J Wouter Jukema; Abbas Dehghan; David-Alexandre Trégouët; Alanna C Morrison; Andrew D Johnson; Christopher J O'Donnell; David P Strachan; Charles J Lowenstein; Nicholas L Smith
Journal:  Circulation       Date:  2019-01-29       Impact factor: 29.690

9.  Potent and rapid reversal of the von Willebrand factor inhibitor aptamer BT200.

Authors:  Shuhao Zhu; James C Gilbert; Zicai Liang; Daiwu Kang; Ming Li; Paul M Tarantino; Bernd Jilma
Journal:  J Thromb Haemost       Date:  2020-06-10       Impact factor: 5.824

10.  Associations Between Blood Biomarkers, Cardiac Function, and Adverse Outcome in a Young Fontan Cohort.

Authors:  Eva van den Bosch; Sjoerd S M Bossers; Vivian P Kamphuis; Eric Boersma; Jolien W Roos-Hesselink; Johannes M P J Breur; Arend D J Ten Harkel; Livia Kapusta; Beatrijs Bartelds; Arno A W Roest; Irene M Kuipers; Nico A Blom; Laurens P Koopman; Willem A Helbing
Journal:  J Am Heart Assoc       Date:  2021-02-24       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.